EQS-News: MPH Health Care AG
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
Die MPH Health Care AG hat am 02.02.2024 erfolgreich 1,5 Mio. Aktien ihrer Beteiligung M1 Kliniken AG an die beiden Vorstände der M1 Kliniken AG, Herrn Attila Strauss und Herrn Kilian Brenske, verkauft. Die beiden Co-CEOs erwarben das Aktienpaket, um ihr unternehmerische Engagement zu verstärken. Die Transaktion unterstreicht das Vertrauen des Managements in die langfristige Performance der M1 Kliniken AG.
MPH Health Care AG-Vorstand, Patrick Brenske, sagt: „Ich begrüße den Schritt des Managements sich an der M1 Kliniken AG zu beteiligen. In den vergangenen 15 Monaten haben die beiden Co-CEOs den Unternehmenswert nahezu verdoppelt. Es stärkt die Motivation, das Unternehmen weiter nachhaltig zu führen und langfristige Werte für alle Aktionäre zu schaffen. Die Skalierung des Geschäftsmodells wird durch diesen Aktienkauf gefördert, da die Co-CEOs nun einen noch stärkeren Anreiz haben, das Wachstum der M1 Kliniken AG voranzutreiben.“ Über die MPH Health Care AG:
05.02.2024 CET/CEST Veröffentlichung einer Corporate News/Finanznachricht, übermittelt durch EQS News - ein Service der EQS Group AG. |
Sprache: | Deutsch |
Unternehmen: | MPH Health Care AG |
Grünauer Straße 5 | |
12557 Berlin | |
Deutschland | |
Telefon: | 030 / 863 21 45 60 |
Fax: | 030 / 863 21 45 69 |
E-Mail: | info@mph-ag.de |
Internet: | www.mph-ag.de |
ISIN: | DE000A289V03, DE000A289VT5 |
WKN: | A289V0 |
Börsen: | Freiverkehr in Berlin, Düsseldorf, Frankfurt (Basic Board), München, Stuttgart, Tradegate Exchange |
EQS News ID: | 1830413 |
Ende der Mitteilung | EQS News-Service |
|
1830413 05.02.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.